Print Page     Close Window     

SEC Filings

10-Q
SERES THERAPEUTICS, INC. filed this Form 10-Q on 05/09/2018
Entire Document
 

SERES THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited, in thousands, except share and per share data)

 

 

 

Three Months Ended March 31,

 

 

 

2018

 

 

2017

 

Revenue:

 

 

 

 

 

 

 

 

Collaboration revenue - related party

 

$

3,766

 

 

$

3,015

 

Grant revenue

 

 

205

 

 

 

 

Total revenue

 

 

3,971

 

 

 

3,015

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development expenses

 

 

23,460

 

 

 

20,143

 

General and administrative expenses

 

 

8,777

 

 

 

8,762

 

Total operating expenses

 

 

32,237

 

 

 

28,905

 

Loss from operations

 

 

(28,266

)

 

 

(25,890

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest income (expense), net

 

 

347

 

 

 

416

 

Total other income (expense), net

 

 

347

 

 

 

416

 

Net loss

 

$

(27,919

)

 

$

(25,474

)

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.69

)

 

$

(0.63

)

Weighted average common shares outstanding, basic and diluted

 

 

40,628,434

 

 

 

40,368,536

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

Unrealized gain (loss) on investments, net of tax of $0

 

$

40

 

 

$

(2

)

Total other comprehensive income (loss)

 

 

40

 

 

 

(2

)

Comprehensive loss

 

$

(27,879

)

 

$

(25,476

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

5



© Seres Therapeutics. All Rights Reserved.